Comparative Pharmacology
Head-to-head clinical analysis: LIBRIUM versus MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIBRIUM versus MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE.
LIBRIUM vs MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to benzodiazepine site on GABA-A receptor, potentiating GABAergic inhibition and increasing chloride ion conductance.
Benzodiazepine that enhances GABA-A receptor activity, increasing chloride ion conductance and neuronal hyperpolarization.
5-25 mg orally 3-4 times daily; or 50-100 mg intramuscularly or intravenously initially, then 25-50 mg 3-4 times daily as needed.
0.5-2 mg slow IV over 2 minutes, may repeat q2-3min; typical total dose 2.5-5 mg. IM: 0.07-0.08 mg/kg (usual 5 mg).
None Documented
None Documented
Terminal elimination half-life of chlordiazepoxide is 24-48 hours; active metabolite desmethyldiazepam has half-life of 36-200 hours; with repeated dosing, effective half-life extends due to accumulation of active metabolites.
Terminal elimination half-life is 1.8-2.5 hours in healthy adults. In critically ill patients or those with hepatic impairment, half-life may extend to 2-6 hours. Obesity may prolong half-life due to increased volume of distribution.
Renal excretion of unchanged drug and metabolites (primarily glucuronide conjugates of chlordiazepoxide and demoxepam, <2% unchanged); approximately 60-70% of a dose appears in urine as metabolites, with 4-9% in feces via biliary elimination.
Primarily renal elimination of hydroxylated metabolites (midazolam 1-hydroxymidazolam and 4-hydroxymidazolam) as glucuronide conjugates. Only 0.03% of unchanged drug is excreted renally. Fecal excretion accounts for <2%.
Category C
Category D/X
Benzodiazepine
Benzodiazepine